AVENUE THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AVENUE THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.91M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($11.65M) | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | ($3.55M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($3.73M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.15M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($25.91M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($21.55M) | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | ($6.24M) | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | ($2.95M) | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | ($2.41M) | Mar 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.08M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($11.28M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($14.54M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.04M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($3.74M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.21M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($26.27M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($21.82M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($11.42M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($2.38M) | Mar 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.65M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.70M | Mar 18, 2024 |
| FY2022 | Oct 31, 2022 | $300.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.25M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.87M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $22.19M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $17.70M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.70M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.83M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($9.03M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($9.45M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.60M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($3.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.61M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($26.26M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($18.22M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($6.80M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($1.63M) | Mar 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.93M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.67M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.85M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $3.96M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.25M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $8.92M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.53M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $22.17M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $197.0K | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $816.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.58M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $509.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $886.0K | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.12M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.16M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.79M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $8.45M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.80M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.58M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.91M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $3.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.36M | Mar 25, 2022 |
| FY2021 | Dec 31, 2019 | $6.80M | Mar 25, 2022 |
| FY2020 | Dec 31, 2018 | ($631.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $19.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($8.25M) | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.49M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($102.58M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($90.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($80.55M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($77.00M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($73.27M) | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | ($68.12M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($42.21M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($20.66M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($8.40M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.86M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.59M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.78M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.71M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $3.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.13M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | $8.75M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.67M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.78M | Mar 12, 2019 |
| FY2018 | Dec 31, 2016 | $197.0K | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (15) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (73) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 18, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 25, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Mar 25, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 2.11M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 341,324 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.77M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 1.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 16.75M | Mar 25, 2022 |
| FY2020 | Dec 31, 2019 | 16.68M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 10.67M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 10.27M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 3.26M | Mar 1, 2018 |